Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
May 06 2024 - 10:15PM
Business Wire
Inocras Hong Kong, in partnership with Cancerinformation.com.hk
Charity Foundation (CICF) and generously sponsored by AstraZeneca
Hong Kong, is pleased to announce the launch of 'HRDetect' Program
offering free BRCA or HRD genetic testing for eligible cancer
patients in Hong Kong and Macau. The testing services will be
performed by the Inocras laboratory in San Diego, which holds
CLIA-certified, CAP-accredited to provide the highest quality and
reliability of test results.
How the Program Works:
Eligible patients in both the private and public sectors can
apply for the free genetic tests through their physicians. The
program will offer BRCA or HRD testing to eligible patients
diagnosed with breast cancer and ovarian cancer, prostate cancer
and pancreatic cancer. Eligible patients are also entitled to free
pre-test or post-test genetic counselling session. With this
program, individuals diagnosed with cancer can gain access to
advanced genetic testing-informed treatment planning and
personalized care.
"We are proud to leverage our cutting-edge technology and
expertise to offer free genetic testing services to eligible cancer
patients in Hong Kong and Macau," said Stephanie Sunkyung Yang, CEO
of Inocras Hong Kong Limited. "Our collaboration with
Cancerinformation.com.hk Charity Foundation and sponsorship from
AstraZeneca Hong Kong highlights our commitment to advancing
precision medicine and providing personalized care to individuals
battling cancer."
“We are delighted to be part of this collaborative effort with
Inocras Hong Kong Limited, along with the generous support from
AstraZeneca Hong Kong. Through this joint initiative with Inocras,
we aim to make a significant difference in the lives of cancer
patients and their families by providing crucial support throughout
their treatment journey,” said Natalie Fong, Chairman of
Cancerinformation.com.hk Charity Foundation. “Our collective
mission is to promote the importance of early detection within the
community, ultimately improving patients’ overall health
outcomes.”
The partnership between Inocras, CICF, and AstraZeneca Hong Kong
signifies a significant step forward in making advanced genetic
testing and precision medicine accessible to cancer patients in the
region. By leveraging Inocras's innovative testing services and
comprehensive genetic analyses, patients can make informed
treatment decisions and may see potential benefits in their overall
health outcomes.
About Inocras Hong Kong Limited:
Inocras Hong Kong Limited, as a subsidiary of Inocras Inc. with
its headquarter in San Diego, the USA(formerly Genome Insight,
Inc), is a pioneering provider of whole genome sequencing and
analytics services for cancer and rare diseases. The company is
dedicated to unlocking the potential of genomic data to enable
precision health for everyone. To learn more, visit
Inocras.com.
About Cancerinformation.com.hk Charity Foundation:
Cancerinformation.com.hk Charity Foundation (CICF) is a local
NGO dedicated to supporting cancer patients and their caregivers in
Hong Kong. With a comprehensive approach, our services encompass
financial aid, psychological counselling, rehabilitation, and
community support programs. Through different public education
initiatives, we strive to promote early detection and improved
access to cancer care and resources within the community. To learn
more, visit https://cicf.org.hk/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506201775/en/
For more information about the free genetic testing program or
media inquiries, please contact: Gordon Cheung Director of Business
Development Inocras Hong Kong Limited Email:
gordon_cheung@inocras.com Phone: +852 3511 6347